NeuroMetrix announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management. The Company has also terminated its at-the-market equity facility it had entered into with Ladenburg Thalmann & Co., Inc. on October 22, 2021.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NURO:
- NeuroMetrix announces publication of study on DPNCheck
- NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
- NeuroMetrix reports over 2000 patients prescribed Quell Fibromyalgia
- NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
- Echo Lake calls for firing of NeuroMetrix CEO Shai Gozani
